overreactionTrillium Therapeutics weakness an overreaction, says Cowen Cowen analyst Boris Peaker said weakness in Trillium Therapeutics due to safety concerns of DLT in Phase 1 dose-escalation trial is an overreaction. Peaker said Tiriium has advanced this study into expansion arms which we believe indicates they have found a therapeutic window and reiterates his Outperform rating.
Read more at:
https://thefly.com/landingPageNews.php?id=2456991